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a b s t r a c t
World Health Organization guidelines recommend that cervical cancer screening programs should
prioritize screening coverage in women aged 30 to 49 years. Decisions about target ages and screening
frequency depend upon local burden of disease, costs, and capacity. We used cost and test performance
data from the START-UP demonstration projects in India, Nicaragua, and Uganda to evaluate the cost-
effectiveness of screening at various start ages, intervals, and frequencies. We calibrated a mathematical
simulation model of cervical carcinogenesis to each country and compared screening with careHPV
(cervical and vaginal sampling), visual inspection with acetic acid (VIA), and cytology between the ages of
25 and 50 years, at frequencies of once to three times in a lifetime, at 5- and 10-year intervals. Screening
with careHPV (cervical sampling) was the most effective and cost-effective strategy in all settings; careHPV
(vaginal sampling) was only slightly less effective. The most critical ages for screening are between ages 30
and 45 years. Within this age range, screening at certain ages may be relatively more cost-effective, but
cancer risk reductions are similar for a given screening test and interval. Screening three times between 30
and 45 years was very cost-effective and reduced cancer risk by 50%.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Cervical cancer is the fourth most common cancer in women,
resulting in an estimated 528,000 incident cases and 266,000 deaths
worldwide in 2012 [1]. Approximately 85% of cases and deaths occur
in the developing world, where the implementation of cytology-
based screening programs to detect and treat precancerous lesions
do not exist, or they have not been effective due to lack of health
delivery infrastructure and limited ﬁnancial resources [2]. Despite
the difﬁculties of implementing organized screening programs,
several clinical and economic studies have suggested that one- and
two-visit screen-and-treat approaches using visual inspection with
acetic acid (VIA) or human papillomavirus (HPV) DNA testing can be
feasible, beneﬁcial, and cost-effective in low-resource settings [3–6].
HPV DNA testing is associated with higher sensitivity than VIA to
detect precancer [7–9], yet VIA is associated with programmatic
advantages, including lower costs and the ability to screen and treat
within a single visit. A public–private collaboration has led to the
development of careHPV (QIAGEN, Gaithersburg, MD), a lower-cost
DNA test that can be used in clinics that lack reliable clean water or
electricity; the performance of careHPV has been validated in
demonstration projects and it has been shown to be cost-effective
when part of a screen-and-treat algorithm in El Salvador [10].
The World Health Organization (WHO) recommends that screen-
ing begin at 30 years of age, with priority given to maximizing
population screening coverage of women aged 30 to 49 years rather
than maximizing the number of screening tests in an individual
woman’s lifetime [11,12]. Recommended screening tests include
HPV testing and VIA, with suggested rescreening intervals of 3 to
5 years following a negative VIA screening result, and no less than
5 years following a negative HPV test [11,12]. Where high quality
cytology (i.e., Pap) programs are already in place, cytology may be
used as a screening test [11]. For HIV-infected women or women
with unknown HIV status in high endemic areas, rescreening
following a negative screening test is recommended within 3 years
[11,12]. The WHO guidelines state that screening even once in a
lifetime is beneﬁcial, and intervals may depend on available
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resources and infrastructure; decisions about the target ages and
frequency of screening depend upon local burden of disease, costs,
and infrastructure, and are left to country-level decision makers [12].
In settings where screening may only take place once, twice, or
three times in a woman’s lifetime, decision makers need informa-
tion on the optimal screening ages and intervals to maximize the
health beneﬁts and value associated with limited screening opp-
ortunities. Using cost and test performance data from the Screen-
ing Technologies to Advance Rapid Testing–Utility and Program
Planning (START–UP) demonstration projects in India, Nicaragua,
and Uganda, our objective was to evaluate the cost-effectiveness
of screening at various start ages, intervals, and frequencies in
resource-limited settings with different epidemiologic proﬁles.
2. Material and methods
2.1. Analytic overview
We used an existing individual-based Monte Carlo simulation
model of the natural history of HPV and cervical cancer to estimate
lifetime health and economic outcomes associated with screening
with HPV DNA testing, VIA, and cytology at selected ages and
intervals [10,14–17]. The model was calibrated to epidemiologic
data from India, Nicaragua, and Uganda. Test performance and cost
data were drawn from the START–UP multi-site demonstration
project conducted in India (Hyderabad), Nicaragua (Masaya Pro-
vince), and Uganda (Kampala) [7,18]; a fourth site in India was not
included in this evaluation. Model outcomes included lifetime risk
of cervical cancer, total lifetime costs (in 2011 international dollars
[I$]), and life expectancy. Cost-effectiveness ratios were expressed
using incremental cost-effectiveness ratios (ICERs), deﬁned as the
additional cost of a particular strategy divided by its additional
health beneﬁt, compared with the next most costly strategy after
eliminating strategies that are dominated (deﬁned as more costly
and less effective, or having higher ICERs than more effective
options). While there is no universal criterion that deﬁnes a
threshold cost-effectiveness ratio, we considered the heuristic that
an intervention with an ICER less than the country’s per capita gross
domestic product (GDP) would be “very cost-effective” and less than
three times per capita GDP would be “cost-effective”[19]. In addition
to value for money, we estimated the ﬁnancial costs of screening to
determine a country’s budget impact over a 1-year period. Consistent
with guidelines for cost-effectiveness analysis [20–22], we adopted a
societal perspective, including costs irrespective of the payer, and
discounted future costs and life-years at a rate of 3% per year to
account for time preferences.
2.2. Mathematical simulation model
The natural history model of cervical carcinogenesis in an indivi-
dual woman is represented as a sequence of monthly transitions
between mutually exclusive health states, including type-speciﬁc
HPV infection status, grade of precancer (i.e., cervical intraepithelial
neoplasia [CIN] grade 2 or 3), and stage of invasive cancer [10,14].
Transition probabilities may vary by age, HPV type, duration of
infection or precancerous lesion status, and prior HPV infection.
Cancer detection can occur through symptoms or via screening. Each
month, death can occur from non-cervical causes or from cervical
cancer after its onset. The model tracks disease progression and
regression, clinical events, and economic outcomes over the lifetime
for each individual woman, which are then aggregated for analysis.
Details of the model parameterization process, including cali-
bration, have been previously published [10,14,15] and are
described in the Appendix. Brieﬂy, we estimated baseline “prior”
input parameter values for natural history transitions using
longitudinal data [23–27]. To reﬂect heterogeneity in age- and
type-speciﬁc HPV incidence between settings, as well as natural
immunity following initial infection and uncertainty in progres-
sion and regression of precancer, we set plausible ranges around
these input parameter values. Repeated model simulations in the
absence of any intervention selected a single random value from
the plausible range for each uncertain parameter, creating a
unique natural history input parameter set. We then computed a
goodness-of-ﬁt score by summing the log-likelihood of model-
projected outcomes for each unique parameter set to represent the
quality of ﬁt to country-speciﬁc epidemiologic data (i.e., calibra-
tion targets). For each country, we selected the top 50 input
parameter sets that produced good ﬁt to the epidemiologic data
to use in analyses as a form of probabilistic sensitivity analysis
[14,15,28]. Model ﬁt to empirical data on age-speciﬁc high-risk
HPV prevalence data from the START–UP projects and age-speciﬁc
cancer incidence is displayed in the Appendix. We report results as
the mean and range of outcomes across these top 50 parameter
sets; incremental cost-effectiveness ratios are reported as the ratio
of the mean costs divided by the mean effects of one strategy
versus another across sets [29].
2.3. Strategies
We assumed available screening tests included careHPV (provi-
der-collected [cervical] and self-collected [vaginal] sampling), VIA,
and conventional cytology, with site-speciﬁc test performance
parameters informed by the START–UP demonstration projects.
Self-collection of vaginal HPV samples does not require pelvic
evaluation, and thus was evaluated as an alternative to provider-
collection. Test performance and treatment parameters are pre-
sented in Table 1 [7,30–36]. For VIA, we assumed that women who
were screen-positive and eligible for cryosurgery were generally
treated at the same clinical visit but that a proportion refused
immediate treatment and either returned for a subsequent visit or
was lost to follow-up; for those not eligible for cryosurgery, we
assumed referral to a secondary facility for further diagnostic testing
and treatment. For careHPV testing, we assumed women were
screened during the ﬁrst visit and returned for a second visit to
obtain results; if they screened positive and were eligible, most
received same-day cryosurgery. Cytology included an initial visit for
screening, a second visit to receive results, a third visit to receive
diagnostic colposcopy and biopsy for screen-positive women, and
if necessary, a fourth visit for treatment. Treatment protocols for
women who were not eligible for immediate cryosurgery, and
management following treatment, were based on current practice
in each country and are documented in the Appendix.
To focus on the ages recommended by the WHO as well as ages
when opportunistic screening may occur, we evaluated each screen-
ing test at the following frequencies, ages, and intervals: (1) once in
a lifetime at ages 25, 30, 35, 40, 45, or 50 years; (2) twice in a
lifetime at ages 25 and 35 years; 30 and 40 years; or 35 and 45
years; and (3) three times in a lifetime at ages 25, 35, and 45 years;
30, 35, and 40 years; 35, 40, and 45 years; or 30, 40, and 50 years. At
each target age in a given screening strategy, the model randomly
selected 70% of women for screening. Thus, for screening at later
ages in strategies involving two or three screenings in a lifetime,
women did not have to have been screened previously in order to
be selected for screening at a later target age.
2.4. Cost data
Cost data (in 2011 I$) are presented in Table 1. Direct medical costs
of screening, diagnosis, and treatment of precancerous lesions were
drawn from the START–UP study sites, and included staff time, clinical
supplies, drugs, clinical equipment, laboratory staff time, laboratory
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supplies, and laboratory equipment. In the START–UP sites, because
women self-collected a vaginal sample for careHPV testing in the
clinics rather than in a community setting, most costs are similar to
those for provider-collected cervical samples. As documented in the
Appendix, we converted local currency units to 2011 I$, a hypothetical
currency that provides a means of translating and comparing costs
among countries, taking into account differences in purchasing power;
we assumed the careHPV test kit was a tradable good valued at US$5.
Women’s time spent traveling, waiting, and receiving care and
transportation costs were dependent upon the facility level and
were derived from START–UP data and the published literature, as
described in the Appendix [5,7,10,16,18,37]. Costs associated with
cancer care by stage include direct medical costs, women’s time
costs, and transportation costs, and were derived from published
studies (see Appendix).
To assess the budget impact of screening at the country level, we
used the individual-based simulation model to estimate the expected
direct medical cost per woman screened, including the costs of
screening and any relevant diagnostic testing and treatment of pre-
cancer, for cost-effective strategies. Wemultiplied the expected cost per
woman screened at each age by the number of women at each of the
target ages in 2015, assuming 70% screening coverage. We report the 1-
year ﬁnancial costs of screening in 2013 US$ instead of I$ to provide a
meaningful estimate to the international and donor communities. This
budget impact analysis did not consider cost offsets from future cancer
cases prevented and patient time and transportation costs.
3. Results
3.1. Reduction in cancer risk
The health impact of once in a lifetime screening associated with
each screening test and age is presented in Fig. 1. Across countries and
Table 1
Baseline values for model variables a.
Variable [Reference] India Nicaragua Uganda
Population coverage of screening program 70% 70% 70%
Loss to follow-up per visitb 15% 15% 15%
Proportion of eligible women receiving immediate cryosurgery following VIAc [30] 70% 70% 70%
Proportion of eligible women receiving immediate cryosurgery following careHPV resultsc 80% 80% 80%
Proportion of eligible women lost to follow-up prior to delayed cryosurgery [30] 10% 10% 10%
Test sensitivity/speciﬁcity for CIN2þ
careHPV (cervical specimen)[7] 90%/95% 78%/89% 89%/82%
careHPV (vaginal specimen)[7] 76%/95% 67%/86% 77%/82%
VIA (30–49 years)[7] 55%/92% 64%/78% 74%/67%
VIA (Z50 years)[7,31–33] 26% /94% 17%/94% 35%/80%
Cytology[7] 74%/98% 41%/94% 69%/49%
Test sensitivity/speciﬁcity for CIN1þ , colposcopyd 50%/96% 95%/68% 95%/51%
Eligibility for cryotherapy [10]
No lesion or CIN1 100% 100% 100%
CIN2 85% 85% 85%
CIN3 75% 75% 75%
Cancer 10% 10% 10%
Effectiveness of cryotherapy [10,34–36] 92% 92% 92%
Effectiveness of cryotherapy/LEEP following colposcopy [10,35] 96% 96% 96%
Direct medical costs [7,18]e
careHPV (cervical specimen)f 9.24 15.61 8.78
careHPV (vaginal specimen)f 8.90 13.48 8.48
VIA 3.55 9.61 2.90
Cytology 15.15 13.71 12.25
Colposcopyg 9.86 15.25 7.08
Colposcopy and biopsyg 30.06 39.48 32.90
Cryotherapy 38.13 33.04 13.49
LEEP NA 133.64 139.54
Direct non-medical costse
Transportation (round-trip, clinic) [5,10,16] 0.08 0.69 4.46
Transportation (round-trip, secondary facility) [5,10,16] 15.29 2.75 10.87
Women’s time (per hour) [37] 1.14 1.41 0.68
Treatment of local cancer (FIGO stages 1a–2a) [5,10,16]e,h 1821 3322 888
Treatment of regional/distant cancer (FIGO stages Z2b) [5,10,16]e,h 2652 4268 1176
a CIN: cervical intraepithelial neoplasia; FIGO: International Federation of Gynecology and Obstetrics; LEEP: loop electrosurgical excision procedure; VIA: visual
inspection with acetic acid. Further details on unit cost assumptions are available in the Appendix.
b Loss to follow-up is deﬁned as the proportion of women who do not return for each subsequent clinical encounter, relative to the previous visit (loss to follow-up
applies to the results visit for careHPV testing, or diagnostic conﬁrmation and treatment visits for cytology or womenwho are ineligible for cryosurgery in a screen-and-treat
approach [i.e., VIA or careHPV testing]).
c We assumed that a slightly higher proportion of screen-positive women (80%) would receive cryotherapy at the HPV results visit than at the screening visit with VIA
(70%). Compliance with same-day cryotherapy after VIA was drawn from the published literature [30], and we assumed that women might be more likely to delay
cryotherapy after VIA than with 2-visit HPV testing, when they would have already received counseling in the screening visit.
d Test performance characteristics of colposcopy in START–UP were derived from the worst diagnosis of the local pathologist relative to the worst diagnosis by a quality
control pathologist (gold standard); we applied the treatment threshold of CIN1þ , although this was not the treatment threshold in START–UP. To derive test performance of
colposcopy, we excluded histological classiﬁcations that were inadequate or with a histological classiﬁcation other than negative, CIN1, CIN2, CIN3, or cancer. Because CIN1 is
not a true underlying health state in the model, performance of colposcopy in the model is based on the underlying health states of no lesion, HPV infection, CIN2, or CIN3.
For a treatment threshold of CIN1, we weighted sensitivity of colposcopy for women with HPV based on the country-speciﬁc prevalence of CIN1 among women with HPV
infections in the START–UP studies.
e All costs are in 2011 international dollars (I$).
f This includes the cost of the careHPV test, which was assumed to be I$5.
g The proportion of colposcopies that were accompanied by a biopsy was drawn from START-UP data as follows: 93.1% (India); 95.6% (Uganda); and 99.5% (Nicaragua).
h All cancer costs presented include the value of women’s time spent pursuing care and transportation to health facilities.
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Fig. 1. Reduction in lifetime risk of cancer, once in a lifetime screening. Reduction in lifetime risk of cancer (y-axis) is displayed for each age at which once in a lifetime
screening was considered (x-axis) for (A) India; (B) Nicaragua; and (C) Uganda. Cancer reduction associated with careHPV (cervical sampling) is displayed by the blue bars;
careHPV (vaginal sampling) by the red bars; VIA by the green bars; and cytology by the purple bars. Error bars display the range in cancer reduction across the 50 good-
ﬁtting input parameter sets. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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ages considered, screening with careHPV (cervical sampling) yielded
the greatest mean reductions in lifetime risk of cancer relative to other
screening tests. Self-collected vaginal sampling with careHPV testing
was slightly less effective due to lower test sensitivity in all sites. VIA
was associated with lower reductions in cancer risk than careHPV
testing, particularly in India, where VIA test sensitivity (CIN2þ thresh-
old) was approximately 20% lower than careHPV with vaginal sam-
pling. Reductions in cancer risk with cytology were low even in India,
where its sensitivity for CIN2þ (74%) was similar to careHPV test-
ing (vaginal sampling), due to the number of required visits bet-
ween screening and necessary treatment resulting in higher loss to
follow-up.
Screening once in a lifetime with careHPV (cervical sampling), the
most effective screening test, achieved the lowest mean reductions in
cancer risk when screening occurred at age 25 years (17.3%) and
highest when screening occurred at age 40 years (24.6%) in India;
lowest at age 50 years (17.0%) and highest at age 30 years (26.2%) in
Nicaragua; and lowest at age 50 years (18.6%) and highest at age 35
years (26.5%) in Uganda (Fig. 1). In every country and at every age,
careHPV (vaginal sampling) was the second most effective, with mean
reductions in cancer risk just a few percentage points below careHPV
(cervical sampling). Screening twice in a lifetime with careHPV
(cervical sampling) was associated with mean reductions in cancer
risk that were lowest when screening occurred at ages 25 and 35 years
(34.7%) and highest when screening occurred at ages 35 and 45 years
(40.6%) in India; lowest at ages 35 and 45 years (39.4%) and highest at
ages 25 and 35 years (42.5%) in Nicaragua; and lowest at ages 35 and
45 years (41.5%) and highest at ages 30 and 40 years (43%) in Uganda
(Appendix). Screening three times in a lifetime with careHPV (cervical
sampling) was associated with mean reductions in cancer risk that
were lowest at ages 30, 35, and 40 years (48.7%) and highest at ages
30, 40, and 50 years (51.3%) in India; lowest at ages 35, 40, and 45
years (48.9%) and highest at ages 25, 35, and 45 years (53.5%) in
Nicaragua; and lowest at ages 35, 40, and 45 years (50.9%) and highest
at ages 25, 35, and 45 years (55.4%) in Uganda (Appendix).
3.2. Cost-effectiveness analysis
The cost-effectiveness of screening for each test, age, frequency,
and interval in India is displayed in Fig. 2A. HPV testing with
Fig. 2. Cost-effectiveness of screening for cervical cancer. The discounted lifetime costs (in 2011 international dollars) and life expectancy associated with each screening
test, age, interval, and frequency are shown for (A) India; (B) Nicaragua; and (C) Uganda. The cost-effectiveness associated with a change from one strategy to a more costly
alternative is represented by the difference in cost divided by the difference in life expectancy associated with the two strategies. Strategies that lie on the efﬁciency curve
dominate those to the right of the curve because they are more effective and either cost less or have a more attractive cost-effectiveness ratio than less effective options. An
incremental cost-effectiveness ratio is shown for each non-dominated strategy and is the reciprocal of the slope of the line connecting the two screening strategies under
comparison. This slope is steeper when the incremental gain in life expectancy per international dollar is greater. I$: 2011 international dollars; VIA: visual inspection with
acetic acid; YLS: year of life saved.
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careHPV (cervical sampling) dominated other screening tests,
which either were more costly and less effective (i.e., cytology,
VIA) or had higher ICERs and were less effective (i.e., VIA). The
strategy with the lowest ICER was careHPV (cervical sampling) at
age 45 years (I$190 per YLS). Screening once in a lifetime at age 40
years yielded greater life expectancy gains and had a slightly
higher ICER (I$330 per YLS). While screening twice in a lifetime at
ages 35 and 45 years was a ranking strategy (I$390 per YLS),
screening twice in a lifetime at either 30 and 40 years or 25 and 35
years with careHPV (cervical sampling) was dominated by screen-
ing three times in a lifetime with careHPV (cervical sampling) at
ages 30, 40, and 50 years (I$580 per YLS). Screening three times in
a lifetime at ages 30, 35, and 40 years (I$1600 per YLS) was the
strategy that achieved the greatest life expectancy gains, with an
ICER well below India’s per capita GDP of I$5240 per YLS.
The cost-effectiveness of screening by test, age, frequency, and
interval in Nicaragua is presented in Fig. 2B. As in India, careHPV
(cervical sampling) dominated other screening tests. In Nicaragua,
screening with careHPV (cervical sampling) at age 35 years was
cost-saving due to the high costs of treating cervical cancer
relative to the costs of screening and treatment, high reductions
in cancer risk attributable to screening, and the high gain in life
expectancy from averting early cancers (estimated cancer inci-
dence in Nicaragua peaks around age 45). Screening twice in a
lifetime with careHPV (cervical sampling) at ages 30 and 40 years
was associated with an ICER of I$50 per YLS. Screening three times
in a lifetime with careHPV (cervical sampling) at ages 30, 35, and
40 years (I$180 per YLS) or 25, 35, and 45 years (I$1200 per YLS)
would be considered very cost-effective, with ICERs falling well
below Nicaragua’s per capita GDP of I$4220.
Cost-effectiveness results for Uganda are displayed in Fig. 2C.
As in India and Nicaragua, careHPV (cervical sampling) dominated
other screening tests. In Uganda, the ICER was lowest when
screening occurred once in a lifetime at age 40 years (I$120 per
YLS); screening once in a lifetime at age 35 years was more
effective and associated with an ICER of I$160 per YLS. Screening
twice per lifetime at ages 30 and 40 years was associated with an
ICER of I$210 per YLS. Screening three times in a lifetime at ages
25, 35, and 45 was the most effective strategy. Screening three
times in a lifetime was very cost-effective at ages 30, 40, and 50
years (I$350 per YLS); ages 30, 35, and 40 years (I$420 per YLS);
and 25, 35, and 45 years (I$1370).
Cost-effectiveness results tables, assuming each country has
decided a priori to screen either once, twice, or three times in a
lifetime, are presented in the Appendix along with additional sen-
sitivity analyses.
3.3. Budget impact
The estimated ﬁnancial costs of screening in 2015, assuming
70% coverage of the target population, are reported in Table 2. If
India were to opt for the strategy with the lowest ICER (i.e.,
careHPV with cervical sampling at age 45 years), the direct
medical costs associated with screening alone would be an
estimated US$34.2 million in 2015. The most effective strategy in
India with an ICER below the country’s per capita GDP (i.e.,
careHPV with cervical sampling at ages 30, 35, and 40 years)
would cost an estimated US$126.5 million in 2015. In Nicaragua,
where once in a lifetime screening with careHPV at 35 years is
cost-saving, the estimated ﬁnancial costs of screening 70% of this
target population in 2015 would be US$0.4 million; the most
effective strategy with an ICER below per capita GDP, screening
with careHPV at ages 25, 35, and 45 years, would cost an estimated
US$1.1 million in 2015. Once in a lifetime screening with careHPV
at age 40 years in Uganda, the strategy with the lowest ICER,
would cost US$0.6 million in 2015, while screening at ages 25, 35,
and 45 would cost an estimated US$3.1 million.
4. Discussion
We incorporated test performance and cost data from the
START–UP demonstration projects in India, Nicaragua, and Uganda
into a mathematical simulation model to determine the optimal
ages, frequencies, and intervals in terms of long-term health and
cost outcomes for limited cervical cancer screening opportunities
in countries with different epidemiologic proﬁles.
We found that, when all screening tests were evaluated,
careHPV (cervical sampling) was the dominant (i.e., most effective
and most cost-effective) strategy in all sites due to superior test
sensitivity and the use of a screen-and-treat approach requiring as
few as two visits. The screening ages associated with the greatest
reductions in lifetime risk of cancer were between 30 and 45 years
of age; screening before age 30 or after age 45 was associated with
lower reductions in cancer risk. These results support WHO
guidelines that advocate for screening to take place between ages
30 and 49 years. However, when identifying a particular age at
which to screen, we observed differences by country. For once in a
lifetime screening, older ages (e.g., 40 or 45 years) were associated
with the greatest reductions in cancer risk in India, while screen-
ing at younger ages (e.g., 30 or 35 years) yielded the greatest
cancer risk reductions in Nicaragua and Uganda due to the
relatively early peaks in cancer incidence in these two countries.
While screening once in a lifetime at age 25 would not be
considered very cost-effective in any country relative to one-
time screening between ages 30 and 45, screening at age 25 may
provide health beneﬁts and be cost-effective if coupled with two
additional screenings between the critical ages of 30 and 45 years.
The WHO guidelines are ambiguous on screening at younger ages,
stating both that cervical cancer screening should not start prior to
30 years of age, and that screening may be extended to younger
ages if there is evidence of a high risk of precancer [12]. Our
Table 2
Financial costs of screening, by strategy, in 2015.
Age group in 2015,
by countrya
Number of women
in target age group
in 2015b [47]
Cost of screening 70%
of the target population
with careHPV (US$)c
India
45 years 7,657,000 34,167,000
40 years 8,446,000 38,768,000
35 & 45 years 16,696,000 76,749,000
30, 40, & 50 years 24,510,000 111,920,000
30, 35, & 40 years 27,077,000 126,547,000
Nicaragua
35 years 45,000 358,000
30 & 40 years 89,000 707,000
30, 35, & 40 years 135,000 1,065,000
25, 35, & 45 years 138,000 1,122,000
Uganda
40 years 135,000 625,000
35 years 179,000 892,000
30 & 40 years 375,000 1,858,000
30, 40, & 50 years 460,000 2,190,000
30, 35, & 40 years 554,000 2,750,000
25, 35, & 45 years 607,000 3,116,000
a We considered non-dominated strategies from Fig. 2.
b The number of women in the target age group includes only those at target
age(s) in 2015.
c US$: 2013 US$. As described in the Methods, the expected cost per woman
screened (including direct medical costs associated with careHPV [cervical sam-
pling], relevant diagnostic testing, and treatment of precancer) were derived from
the mathematical simulation model. Patient time and transportation costs are not
included in this budget impact analysis.
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ﬁndings suggest that the health and economic impact of extending
screening to women under 30 years depends upon cancer inci-
dence in younger women and the likelihood of access to subse-
quent screenings later in life. While screening once in a lifetime at
age 50 would not be considered cost-effective in any of these
countries, screening at 50 with HPV testing may be very cost-
effective and provide health beneﬁts if coupled with earlier
screenings between 30 and 45 years in India and Uganda, due to
sustained high cancer incidence at later ages.
In all 3 countries evaluated, when all screening tests, frequen-
cies and age combinations were compared, screening three times
in a lifetime with careHPV at adequate intervals and at critical ages
provided good value for money. The addition of a third screening
reduced cancer risk by an additional 10% relative to screening
twice in a lifetime. When three screenings in a woman’s lifetime
are feasible, screening at either 5- or 10-year intervals may be very
cost-effective. This is consistent with WHO guidelines, which
recommend a minimum interval of 5 years following a negative
HPV test [11,38]. In India, screening three times in a lifetime at 30,
35, and 40 years was associated with the greatest life expectancy
gains compared to other strategies considered, and was very cost-
effective. In Nicaragua and Uganda, screening three times at 30,
35, and 40 years was also very cost-effective, and only slightly less
effective than screening three times at 25, 35, and 45 years.
While screening up to three times in a lifetime would be
considered very cost-effective using per capita GDP as a bench-
mark for cost-effectiveness, it is important to consider the con-
sequences of varying this threshold and to note the limitations of
selecting it. In each country considered, at least one strategy for
screening three times per lifetime is associated with an ICER that
is approximately 25% to 30% of per capita GDP, and would thus be
considered very cost-effective even if the threshold were lowered
substantially. Although this benchmark is promoted by the WHO-
CHOICE program [39], the categorization of an intervention as
cost-effective based on the relation of its ICER to per capita GDP
may not lead to the best allocation of scarce resources if there are
other necessary and feasible interventions with greater value for
public health dollars that remain unfunded [40]. Furthermore,
information on the value for money is not equivalent to afford-
ability, or the ﬁnancial impact of a program on a payer’s budget
[40]. To provide information on affordability, we present estimates
of the 1-year ﬁnancial cost of a screening program that would
cover 70% of the target population in each country in 2015 for each
of the strategies that would be considered very cost-effective.
While both the cost-effectiveness proﬁle and recurrent ﬁnancial
costs must be favorable to implement a sustainable screening
program, decision makers responsible for priority setting will also
need information on the programmatic investments that will be
necessary to scale up infrastructure, train personnel, and conduct
social marketing campaigns, as well as how the relative costs and
beneﬁts of cervical cancer screening compare to other health
interventions under consideration. Ultimately, the affordability of
screening programs in these settings will likely depend upon the
extent of ﬁnancial assistance from donors.
Our objective was to evaluate the cost-effectiveness of screen-
ing at various start ages, intervals, and frequencies in women who
are past the primary target age for HPV vaccination [41]. For these
two to three generations of women in low-resource settings,
screening remains the only recommended option for cervical
cancer prevention. As HPV vaccination programs are introduced
and scaled up, it will be important to consider the impact of young
adolescent HPV vaccination on screening protocols. Although
screening in the context of HPV vaccination will be associated
with higher ICERs as the relative beneﬁts of screening decrease,
particularly following next-generation vaccines with fewer
required doses and protection against more HPV types [42], it will
be critical to evaluate the optimal screening start age, frequency,
and interval in vaccinated cohorts and in the general population,
dependent upon vaccination coverage. Additional questions about
the impact of vaccinating older women on optimal screening age
and frequency will also need to be addressed, as recent data from
bivalent and quadrivalent HPV vaccine trials suggest that the
vaccines are somewhat protective against persistent HPV16/18
infections in older women [43,44].
There are several limitations to this analysis. We did not model
all screening strategies covered by the WHO guidelines, such as
HPV testing followed by VIA triage and, in settings with high
coverage cytology programs, HPV testing followed by colposcopy
[11]. Instead, we restricted our analysis to screening tests that
were evaluated in the START–UP study in order to use country-
speciﬁc data on costs and test performance. We also did not
evaluate every possible screening interval starting with the WHO-
recommended minimum interval, as it does not seem realistic for
health care systems in low-resource settings to have the capabil-
ities to recall women at precise intervals. Rather, we attempted to
provide insight about general interval ranges (i.e., 5 to 10 years).
We assumed that screening coverage at each target age in a given
strategy was random and not conditioned upon a woman receiv-
ing screening at the previous ages. Thus, for screening three times
in a lifetime, each woman in the model had an opportunity to
receive screening at each of the speciﬁed ages, resulting in slightly
greater health beneﬁts than if we had assumed the same women
are consistently being screened (or not) at each age. While the
WHO guidelines recommend follow-up within 3 years following a
negative screening test in populations with a high burden of HIV
[11], we did not consider shorter intervals than 5 years in Uganda.
Many of the countries with a high prevalence of HIV are in Sub-
Saharan Africa, where currently available resources limit access to
more frequent screening. We did not consider the possible harms
of overtreatment. Costing estimates for screening and treatment of
precancer were based upon the START–UP study, and thus do not
reﬂect programmatic costs associated with scale-up, nor do they
reﬂect potential economies of scale associated with screening at
the country level. For all 3 countries, the cost of careHPV with
vaginal sampling was based on collection of samples at the clinic.
Thus, we did not capture potentially lower costs and greater
population coverage associated with home collection of HPV
samples [45,46], which might make vaginal sampling as or more
attractive than cervical sampling at the clinic even if acc-
ompanied by reduced test sensitivity.
There are also limitations surrounding our model calibration
approach. While we used HPV prevalence data from the START–UP
study populations, in Nicaragua and India data were only available
for women aged 30 to 49 years (in Uganda, data were available
for women aged 25 to 60 years). Furthermore, model-predicted
cancer incidence at younger ages in Uganda may contribute to the
attractiveness of screening in women under 30 years; there rem-
ains uncertainty surrounding the impact of screening at 25 years
in all 3 sites. Additional limitations pertaining to costing and mod-
eling assumptions are described in the Appendix.
From a program planning perspective, it will be difﬁcult to
target precise ages and intervals (in the case of more than one
screening) for cervical cancer screening in settings where access to
health care is limited. These ﬁndings provide reassurance that the
most critical screenings occur in a wide age range (30 to 45 years),
for countries with varying epidemiologic proﬁles. Within this age
range, screening at certain ages may be relatively more cost-
effective, but reductions in cancer risk are similar for a given
screening test and interval. When screening is only available once
in a woman’s lifetime, it is not possible to set a precise target age
at which screening should occur in all settings. Among once in a
lifetime screening strategies, screening at age 30 years was the
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most effective strategy that was also very cost-effective in
Nicaragua and Uganda (Appendix). However, screening only
once at this early age was cost-prohibitive in India. These
ﬁndings highlight the need for cancer registration in low-
resource settings, as narrowing the optimal window for once
in a lifetime screening may be informed by age-speciﬁc cervical
cancer incidence.
In 2012, there were nearly 1 billion women aged 30 to 49 years;
most of these women have not been screened for cervical cancer
[38]. Using cost and test performance data from screening dem-
onstration projects in 3 countries with different epidemiologic
proﬁles, we found that screening with HPV testing three times in a
lifetime between 30 and 45 years is very cost-effective and can
reduce cancer risk by approximately 50%. It is reassuring to note
that precise targeting of age within this critical range is not needed
to reap this beneﬁt and that even screening with HPV testing twice
in a lifetime can achieve high reductions in cancer risk. Despite
evidence of value for money, considerations of affordability and
sustainability of such strategies will be critical to assess in low-
resource settings.
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Appendix. When and how often to screen for cervical cancer
in three low- and middle-income countries: A cost-
effectiveness analysis
This Appendix provides additional details on methods, assump-
tions, and results presented in the main manuscript.
Model calibration
Overview of the calibration process
Details of the model development process, including initial
parameterization and calibration, have been previously published
[48]. Derivation of model parameter values requires an iterative
process involving comprehensive literature reviews, data synthesis
and analysis, consultations with experts, and explorations of the
inﬂuence of uncertain parameters and assumptions in the model.
Baseline HPV incidence rates, as a function of genotype and age, were
derived from published data from a prospective cohort of sexually
active women aged 15–85 years in Bogota, Colombia [49]. Because
HPV incidence is known to vary by population as a function of sexual
behaviors, age-speciﬁc HPV incidence and natural immunity follow-
ing initial infection were considered important candidates for cali-
bration. Transitions occurring from the HPV state (i.e., time-dep-
endent rates of HPV clearance and progression by genotype) were
informed by longitudinal data from the control arm of the Costa Rica
Vaccine Trial [50]. Type-speciﬁc data on CIN2 and CIN3 regression
and progression are limited [51–56], so these parameters were also
candidates for calibration. Because of the computational intensity of
microsimulation models, we selected parameters for calibration
based on the availability of (1) a range of plausible values and
(2) good empirical data to inform calibration targets (i.e., high-risk
HPV prevalence to calibrate HPV incidence rates; cancer incidence to
calibrate CIN2 and CIN3 regression and progression rates).
To calibrate the model, we set plausible search ranges around
baseline input values for age- and type-speciﬁc HPV incidence, as
well as natural immunity following initial infection and progression
and regression of CIN, and performed repeated model simulations
in the absence of any preventive intervention. For each simulation,
we randomly selected a single value for each of the uncertain
parameters from the identiﬁed plausible range, creating a unique
vector of parameter values (i.e., parameter “set”). Following over
1,475,000 repeated samplings, we identiﬁed the parameter sets
with the highest correspondence to the empirical calibration target
data by calculating and aggregating the log-likelihood of model-pro-
jected outcomes. We used the 50 parameter sets with the highest
likelihood scores (i.e., best overall ﬁt to the empirical data) from
each country for analysis to capture uncertainty in the model para-
meters as a form of probabilistic sensitivity analysis. We report
results as a mean and a range of outcomes across these top 50 para-
meter sets; incremental cost-effectiveness ratios are reported as the
ratio of the mean costs divided by the mean effects of one strategy
versus another across sets.
Calibration targets
We assessed model ﬁt by observing projected model outcomes of
age-speciﬁc prevalence of high-risk HPV and age-speciﬁc cancer
incidence relative to empirical data. The scoring algorithms for India
and Nicaragua included age-speciﬁc prevalence of high-risk HPV and
age-speciﬁc cervical cancer incidence. For Uganda, only age-speciﬁc
cancer incidence was included in the scoring algorithm, as we obs-
erved a better ﬁt to cancer incidence data when we did not include
HPV prevalence in the scoring algorithm; however, we still considered
visual ﬁt to HPV prevalence to arrive at the ﬁnal scoring algorithm.
Age-speciﬁc prevalence of high-risk HPV was drawn from
START–UP data on careHPV positivity using a cut-off ratio cut-
point of 0.5 relative light units (Tables A1–A3). For each age group,
we derived a 95% binomial conﬁdence interval around the point
prevalence, which comprised the calibration target. The likelihood
function for each age group was assumed to follow a binomial
distribution.
Table A1
Age-speciﬁc prevalence of high-risk HPV, India [7]a.
Age group Number of women Number of women
with high-risk HPV
Prevalence (95% CI)
30–34 years 1949 214 0.11 (0.10, 0.13)
35–39 years 1158 99 0.09 (0.07, 0.10)
40–44 years 708 76 0.11 (0.09, 0.13)
45–49 years 687 85 0.12 (0.10, 0.15)
a HPV positivity was based on a cut-off of 0.5 relative light units.
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Age-speciﬁc cancer incidence was drawn from registries in
Cancer in Five Continents [57] for India and Uganda, and from
Globocan for Nicaragua due to the lack of a cancer registry [58]
(Tables A4–A6). The likelihood function for each age group was
assumed to follow a normal distribution.
Composite goodness-of-ﬁt scores for each input parameter set
were generated by summing the log likelihood of each model
outcome (i.e., age-speciﬁc HPV prevalence, age-speciﬁc cancer
incidence). The 50 input parameter sets with the highest
goodness-of-ﬁt scores thus yielded the model outputs that were
simultaneously closest to all calibration targets, and were selected
for analysis. Figs. A1–A6 display model ﬁt to epidemiologic data on
age-speciﬁc prevalence of high-risk HPV and age-speciﬁc cancer
incidence in each country.
Cost data
Direct medical costs: Screening, diagnosis, and treatment of
precancerous lesions
The direct medical costs of screening, diagnosis, and treatment
of precancerous lesions were drawn from the Screening Technol-
ogies to Advance Rapid Testing for Cervical Cancer Prevention–
Utility and Program Planning (START–UP) demonstration studies
in India (Hyderabad), Nicaragua (Masaya Province), and Uganda
(Kampala). Direct medical costs included clinical staff time, clinical
supplies, drugs, clinical equipment, laboratory staff time, labora-
tory supplies, and laboratory equipment.
We report costs in 2011 international dollars (I$) to facilitate
comparisons across regions. The relevant GDP deﬂators were
applied to local currency units to inﬂate to year 2011 levels, and
local currency units were then converted to international dollars
by means of purchasing power parity (PPP) exchange rates [59].
The exceptions were for equipment, which was generally procured
in the United States, and the cost of the careHPV test kit, which
was assumed to be US$5. For these tradable goods, one interna-
tional dollar is equivalent to one U.S. dollar. Costs are reported in
Table 1 of the main manuscript.
Cost of cancer care by stage
Costs associated with cancer care by stage (Local vs. Regional or
Distant), including direct medical costs, women’s time costs for
time spent receiving care, women’s transportation costs to health
facilities, and cancer staging costs were derived from previous
analyses and converted to 2011 I$ as described above. Cancer care
costs in India were based on primary data [60], while costs from
Uganda were based on primary data from Kenya, as we have
previously described [60,61]. Cancer care costs from Nicaragua
were based on primary data from the cost of treating cancer in El
Salvador (excluding staging costs) [62]. To adjust cancer costs from
El Salvador to the setting of Nicaragua, we assumed direct medical
costs were reduced by the ratio of WHO-CHOICE inpatient bed-day
Table A2
Age-speciﬁc prevalence of high-risk HPV, Nicaragua [7]a.
Age group Number of women Number of women
with high-risk HPV
Prevalence (95% CI)
30–34 years 1693 310 0.18 (0.17, 0.20)
35–39 years 1141 184 0.16 (0.14, 0.18)
40–44 years 933 125 0.13 (0.11, 0.16)
45–49 years 878 121 0.14 (0.12, 0.16)
a HPV positivity was based on a cut-off of 0.5 relative light units.
Table A3
Age-speciﬁc prevalence of high-risk HPV, Uganda [7]a.
Age group Number of women Number of women
with high-risk HPV
Prevalence (95% CI)
25–34 years 1367 426 0.31 (0.28, 0.34)
35–44 years 1131 284 0.25 (0.23, 0.28)
45–54 years 558 127 0.22 (0.19, 0.26)
55–60 years 90 28 0.31 (0.22, 0.42)
a HPV positivity was based on a cut-off of 0.5 relative light units. We did not
include HPV prevalence in our scoring algorithm for Uganda, although we did
consider visual ﬁt to HPV prevalence.
Table A4
Age-speciﬁc cervical cancer incidence, India (Nagpur registry, 1998–2002) [57]a.
Age group Cases Rate per 100,000 women (95% CI)
20–24 years 9 1.8 (0.6, 2.9)
25–29 years 11 2.3 (0.9, 3.6)
30–34 years 43 10.6 (7.4, 13.7)
35–39 years 62 16.9 (12.7, 21.1)
40–44 years 90 32.4 (25.7, 39.1)
45–49 years 107 46.2 (37.5, 55.0)
50–54 years 105 58.9 (47.6, 70.1)
55–59 years 70 52.4 (40.1, 64.7)
60–64 years 104 75.0 (60.6, 89.4)
65–69 years 71 62.5 (47.9, 77.0)
70–74 years 44 57.6 (40.6, 74.6)
Z75 years 9 26.8 (9.3, 44.2)
a Although our scoring algorithm included cancer incidence in women aged 30
to 49 years, we considered visual ﬁt to all age groups.
Table A5
Age-speciﬁc cervical cancer incidence, Nicaragua (GLOBOCAN 2012) [58].
Age group Cases Rate per 100,000 women (95% CI)
40–44 years 123 78.7 (64.8, 92.6)
45–49 years 112 85.4 (69.6, 101.2)
50–54 years 102 88.4 (71.2, 105.6)
55–59 years 85 88.1 (69.4, 106.8)
60–64 years 51 84.0 (61.0, 107.1)
65–69 years 37 80.8 (54.8, 106.8)
70–74 years 30 74.6 (47.9, 101.3)
Z75 years 45 70.3 (49.8, 90.8)
Table A6
Age-speciﬁc cervical cancer incidence, Uganda (Kyadondo registry, 2003–2007)
[57]a.
Age group Cases Rate per 100,000 women (95% CI)
25–29 years 42 7.6 (5.3, 9.9)
30–34 years 84 26.5 (20.8, 32.2)
35–39 years 111 53.7 (43.7, 63.7)
40–44 years 138 99.7 (83.1, 116.3)
45–49 years 105 121.7 (98.4, 145.0)
50–54 years 108 181.3 (147.1, 215.5)
55–59 years 59 163.2 (121.6, 204.8)
60–64 years 68 199.7 (152.2, 247.2)
65–69 years 33 145.8 (96.1, 195.6)
70–74 years 35 175.0 (117.0, 233.0)
a Although our scoring algorithm included cancer incidence in aged 40 years
and above, we considered visual ﬁt to all age groups.
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Fig. A3. Selected model output from the top 50 input parameter sets compared with
empirical data (i.e., calibration targets) on age-speciﬁc prevalence of high-risk HPV in
Uganda, based on a relative light unit cut-off value of 0.5 in the START–UP studies [7].
Bold lines represent the 95% conﬁdence intervals around the empirical data, and gray
circles represent model output from each of the top 50 input parameter sets.
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Fig. A4. Selected model output from the top 50 input parameter sets compared
with empirical data (i.e., calibration targets) on age-speciﬁc cancer incidence in
India (Nagpur registry, 1998–2002) [57]. Bold lines represent the 95% conﬁdence
intervals around the empirical data, and gray circles represent model output from
each of the top 50 input parameter sets.
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Fig. A5. Selected model output from the top 50 input parameter sets compared
with empirical data (i.e., calibration targets) on age-speciﬁc cancer incidence in
Nicaragua (GLOBOCAN 2012) [58]. Bold lines represent the 95% conﬁdence intervals
around the empirical data, and gray circles represent model output from each of
the top 50 input parameter sets.
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Fig. A6. Selected model output from the top 50 input parameter sets compared
with empirical data (i.e., calibration targets) on age-speciﬁc cancer incidence in
Uganda (Kyadondo registry, 2003–2007) [57]. Bold lines represent the 95%
conﬁdence intervals around the empirical data, and gray circles represent model
output from each of the top 50 input parameter sets.
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Fig. A2. Selected model output from the top 50 input parameter sets compared with
empirical data (i.e., calibration targets) on age-speciﬁc prevalence of high-risk HPV in
Nicaragua, based on a relative light unit cut-off value of 0.5 in the START–UP studies
[7]. Bold lines represent the 95% conﬁdence intervals around the empirical data, and
gray circles represent model output from each of the top 50 input parameter sets.
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Fig. A1. Selected model output from the top 50 input parameter sets compared
with empirical data (i.e., calibration targets) on age-speciﬁc prevalence of high-risk
HPV in India (Hyderabad), based on a relative light unit cut-off value of 0.5 in the
START–UP studies [7]. Bold lines represent the 95% conﬁdence intervals around the
empirical data, and gray circles represent model output from each of the top 50
input parameter sets.
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costs at a teaching hospital (for cancer center procedures) or
WHO-CHOICE outpatient procedures at a secondary-level hospital
(for regular follow-up care after cancer treatment) in Nicaragua
relative to El Salvador; women’s time costs were reduced by the
ratio of wages (in 2011 I$) in Nicaragua relative to El Salvador, and
transportation and incidental costs were reduced by the ratio of
GNI per capita (in 2011 I$). Costs are reported in Table 1 of the
main manuscript.
Women’s time and transportation costs
We derived women’s time costs from the United Nations
Development Programme Human Development Indicator,
“Estimated GNI per capita, female”, which was derived from
the ratio of female to male wage, female and male shares of
economically active population, and gross national income
(GNI) and reported in constant 2011 I$ [37]. We assumed this
represented annual income for working 40 h per week, 50
weeks per year to estimate an average hourly wage (Table 1).
Estimates for time spent traveling, waiting, and receiving
care was dependent upon the facility level where care was
assumed to take place (Table A7). Women’s time estimates for
round-trip transportation and waiting were obtained from
prior studies in El Salvador (for Nicaragua) [62], India, and
Kenya (for Uganda) (Table A8) [60,61]. Estimates of women’s
time spent receiving a procedure were based on site-speciﬁc
data from the START–UP demonstration projects, with staff
time spent on the procedure (excluding preparation and
registration time, which we assumed were built into patient
waiting time) used as a proxy for women’s procedure time.
Round-trip transportation costs to each health facility level
were obtained from previous analyses [60,61,62] and con-
verted to 2011 I$; these are reported in Table 1 of the main
manuscript.
Protocols for treatment of precancer
We assumed that VIA was primarily a one-visit strategy, with
women receiving screening and, if eligible, treatment with cryother-
apy in the same visit at a primary facility. To account for delayed cry-
otherapy due to menses, equipment malfunction, or a woman’s desire
to discuss treatment with her family, we assumed 70% of women
would receive same-day cryotherapy, while the remaining women
would delay treatment. We assumed HPV DNA testing was primarily a
two-visit strategy, where screening occurred during the ﬁrst visit and
women returned to the clinic to receive results (and treatment with
cryotherapy, if screen-positive and eligible) in a second visit. To
account for the fact that women in a two-visit strategy have had the
opportunity to consider the possibility of treatment prior to receiving
results, we assumed 80% would receive same-day cryotherapy, with
the remaining women delaying treatment. Women who delayed
treatment accrued the time and transportation costs of an additional
clinic visit unless they were lost to follow-up.
Women who screened positive with either VIA or HPV DNA
testing who were ineligible for cryotherapy were assumed to
be referred to a secondary facility for colposcopy and subsequent
treatment. Treatment protocols were based on information from in-
country clinicians familiar with standard of care and availability of
and preferences for treatment options. In Hyderabad, we assumed
that, upon a histologic diagnosis of CIN1, CIN2, or CIN3, women rece-
ived cryotherapy at a secondary facility. In Nicaragua, we assumed
that a histologic diagnosis of CIN1 was followed by cryotherapy and
CIN2/3 was followed by LEEP at a secondary facility. In Uganda, we
assumed that, upon a histologic diagnosis of CIN1, women received
cryotherapy at a secondary facility; a histologic diagnosis of CIN2/3
was followed by cryotherapy for approximately 80% of women, and
Table A7
Location of Service Delivery for Screening, Diagnosis, and Treatment of Precancerous Lesions and Cancera.
Procedure Location of services
HPV DNA test Primary facility
Cytology test Primary facility
VIA test Primary facility
Colposcopy/biopsy Secondary facility
Cryotherapy Primary facility (for women eligible for screen-and-treat cryotherapy)
Secondary facility (for women ineligible for screen-and-treat cryotherapy
LEEP Secondary facility
Follow-up visits (after cryotherapy or LEEP) Primary facility (for examinations and Pap)
Secondary facility (if colposcopy is necessary)
Cancer treatment Tertiary facility
a HPV: human papillomavirus; LEEP: loop electrosurgical excision procedure; VIA: visual inspection with acetic acid.
Table A8
Women’s Time Spent Receiving Care a.
Procedure Time Spent Receiving Care (min)
Hyderabad
[7,60]
Nicaragua
[7,62]
Uganda
[7,60]
Screening
Wait time 60 15 90
Procedure time 15 20 15
Transport time (round-trip) 60 90 220
Receiving results (negative)b 5 2 10
Receiving results (positive) 15 5 15
Diagnosis
Wait time 120 150 180
Procedure time 42 37 35
Transport time (round-trip) 240 90 340
Treatment of precancer: screen-and-treat cryotherapyc
Wait time 60 150 90
Procedure time 30 35 30
Transport time (round-trip) 60 90 220
Treatment of precancer: LEEP
Wait time NA 150 180
Procedure time NA 25 25
Transport time (round-trip) NA 90 340
a I$: international dollars. LEEP: loop electrosurgical excision procedure.
b Applicable to careHPV and Pap screening.
c We assumed most eligible women received cryotherapy in the same visit they
received screening results (i.e., initial screening visit with VIA; second visit for HPV
testing). Thus, additional transportation time was only accrued for women who
delayed cryotherapy. Screen-and-treat cryotherapy was assumed to take place at a
primary facility. For women who received cryotherapy following diagnostic con-
ﬁrmation of CIN, wait time and transport time were the same as for LEEP, as
cryotherapy was assumed to take place at a secondary facility.
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LEEP for approximately 20% of women, and treatment occurred at a
secondary facility.
We assumed cytology required separate visits for screening
(primary facility), receiving results (primary facility), colposcopy
(secondary facility), and subsequent treatment (secondary facility).
Loss-to-follow-up rates impact cost accrual in the microsimu-
lation model, and we have the ﬂexibility to input differential loss-
to-follow-up for each visit (i.e., results, cryotherapy (if delayed),
diagnostic conﬁrmation, and treatment following diagnostic con-
ﬁrmation). In the base case, we assumed 10% of women would be
lost to follow-up if subject to delayed cryotherapy in a screen-and-
treat strategy (i.e., VIA or HPV testing). We assumed visits for
screening results, diagnostic conﬁrmation, and treatment follow-
ing diagnostic conﬁrmation were each associated with 15% loss-to-
follow-up.
Following treatment of precancerous lesions with either
cryotherapy or LEEP, we assumed the setting-speciﬁc follow-up
protocols as used in the START–UP demonstration studies
(Table A9). We included direct medical costs of each procedure,
as well as women’s time and transportation costs (as shown in
Table 1 of the main manuscript). While women in the START–
UP studies could be seen prior to scheduled follow-up visits as
necessary, we did not have data on these unscheduled visits.
Treatment complications in each site were very rare, so we did
not consider these costs in the base case analysis.
Supplementary results
Reduction in cancer risk
The health impact of screening two and three times in a life-
time for each screening test and age combination considered is
displayed in Figs. A7–A12.
Cost-effectiveness results, all screening tests, start ages, and
frequencies
Fig. 2 from the main text is displayed in tabular form in Tables
A10–A12.
Cost-effectiveness results for careHPV, by frequency of screening
Table A13 displays the health beneﬁts and cost-
effectiveness assuming each country has decided a priori to
screen either once in a lifetime; twice in a lifetime; or three
times in a lifetime at speciﬁc targeted age(s) with the domi-
nant strategy careHPV (cervical sampling). In India, assuming
screening will take place once in a lifetime, screening at either
45, 40, or 35 years (in order of increasing effectiveness) had
ICERs that were well-below India’s per capita GDP and there-
fore would be considered very cost-effective. Assuming
Table A9
Follow-up protocols after treatment of precancerous lesionsa.
Treatment Hyderabad Nicaragua Uganda
Cryotherapy 1 year Cytology/Colposcopy 1 year Cytology 6 week exam
1 year Cytology/Colposcopyb
LEEP NA 1 year Cytology 6 week exam
1 year Cytology
1 year Colposcopy, as neededb
a LEEP: loop electrosurgical excision procedure. Follow-up protocols were based on the START–UP demonstration study in each setting. We included direct medical costs
and women’s time and transportation costs for each procedure. A 6 week visual exam was associated with the same costs as VIA at the primary facility. Cytology was
assumed to take place at a primary facility, while colposcopy was assumed to take place at a secondary facility.
b Colposcopy at 1 year was performed as needed in Uganda. Approximately 15% of women who received treatment required a colposcopy and biopsy at 1 year for
suspected recurrence.
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Fig. A7. Reduction in lifetime risk of cancer, screening twice in a lifetime, India.
Reduction in lifetime risk of cancer (y-axis) is displayed for each age combination at
which twice in a lifetime screening was considered (x-axis) for India. Cancer
reduction associated with careHPV (cervical sampling) is displayed by the blue
bars; careHPV (vaginal sampling) by the red bars; VIA by the green bars; and
cytology by the purple bars. Error bars display the range in cancer reduction across
the 50 good-ﬁtting input parameter sets. (For interpretation of the references to
color in this ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. A8. Reduction in lifetime risk of cancer, screening three times in a lifetime,
India. Reduction in lifetime risk of cancer (y-axis) is displayed for each age
combination at which three screenings in a lifetime were considered (x-axis) for
India. Cancer reduction associated with careHPV (cervical sampling) is displayed by
the blue bars; careHPV (vaginal sampling) by the red bars; VIA by the green bars;
and cytology by the purple bars. Error bars display the range in cancer reduction
across the 50 good-ﬁtting input parameter sets. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version
of this article.)
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screening will take place twice per lifetime, screening at either
35 and 45 years, or 30 and 40 years (in order of increasing
effectiveness) would be very cost-effective. Assuming screen-
ing will take place three times per lifetime in India, it would be
very cost-effective at either 30, 40, and 50 years, or 30, 35, and
40 years (in order of increasing effectiveness). Assuming all
ages and frequencies considered are available, screening once
in a lifetime at 35 years becomes dominated by screening once
at 40 years, and screening twice in a lifetime at 30 and 40 years
becomes dominated by screening twice at 35 and 45 years.
Screening three times in a lifetime at 30, 35, and 40 years is
associated with the highest population-level gains in life
expectancy, and with an ICER of I$1600 per YLS is very cost-
effective.
In Nicaragua, assuming screening is available only once per
lifetime, screening at age 35 will be cost-saving. Screening once at
age 30 will be more effective, and with an ICER of I$60 per YLS is
very cost-effective. Screening once at age 25 is associated with the
highest gains in life expectancy, and would be considered cost-
effective with an ICER of I$5750 per YLS. Assuming screening is
available twice per lifetime, screening at 35 and 45 years would be
cost-saving, and screening at 25 and 35 years will cost I$360 per
YLS. If screening is available three times per lifetime, screening at
30, 40, and 50 years would be I$30 per YLS, while screening at 30,
35, and 40 years or 25, 35, and 45 years (in order of increasing
effectiveness) would be very cost-effective. Assuming all ages and
frequencies considered are available, screening once at age 35 will
be cost-saving and screening twice per lifetime at 30 and 40 years
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Fig. A9. Reduction in lifetime risk of cancer, screening twice in a lifetime,
Nicaragua. Reduction in lifetime risk of cancer (y-axis) is displayed for each age
combination at which two screenings in a lifetime were considered (x-axis) for
Nicaragua. Cancer reduction associated with careHPV (cervical sampling) is
displayed by the blue bars; careHPV (vaginal sampling) by the red bars; VIA by
the green bars; and cytology by the purple bars. Error bars display the range in
cancer reduction across the 50 good-ﬁtting input parameter sets. (For interpreta-
tion of the references to color in this ﬁgure legend, the reader is referred to the web
version of this article.)
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Fig. A10. Reduction in lifetime risk of cancer, screening three times in a
lifetime, Nicaragua. Reduction in lifetime risk of cancer (y-axis) is displayed for
each age combination at which three screenings in a lifetime were considered (x-
axis) for Nicaragua. Cancer reduction associated with careHPV (cervical sampling)
is displayed by the blue bars; careHPV (vaginal sampling) by the red bars; VIA by
the green bars; and cytology by the purple bars. Error bars display the range in
cancer reduction across the 50 good-ﬁtting input parameter sets. (For interpreta-
tion of the references to color in this ﬁgure legend, the reader is referred to the web
version of this article.)
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Fig. A11. Reduction in lifetime risk of cancer, screening twice in a lifetime,
Uganda. Reduction in lifetime risk of cancer (y-axis) is displayed for each age
combination at which two screenings in a lifetime were considered (x-axis) for
Uganda. Cancer reduction associated with careHPV (cervical sampling) is displayed
by the blue bars; careHPV (vaginal sampling) by the red bars; VIA by the green
bars; and cytology by the purple bars. Error bars display the range in cancer
reduction across the 50 good-ﬁtting input parameter sets. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of
this article.)
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Fig. A12. Reduction in lifetime risk of cancer, screening three times in a
lifetime, Uganda. Reduction in lifetime risk of cancer (y-axis) is displayed for each
age combination at which three screenings in a lifetime were considered (x-axis)
for Uganda. Cancer reduction associated with careHPV (cervical sampling) is
displayed by the blue bars; careHPV (vaginal sampling) by the red bars; VIA by
the green bars; and cytology by the purple bars. Error bars display the range in
cancer reduction across the 50 good-ﬁtting input parameter sets. (For interpreta-
tion of the references to color in this ﬁgure legend, the reader is referred to the web
version of this article.)
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will cost I$50 per YLS; screening three times at 30, 35, and 40
years or 25, 35, and 45 years are associated with ICERs of I$180 per
YLS and I$1200 per YLS, respectively, and would be very cost-
effective.
In Uganda, if screening is only available once in a lifetime,
screening would be very cost-effective at either age 40, 35, or 30
years (in order of increasing effectiveness), with an ICER of I$260 per
YLS or less. If screening is available twice in a lifetime, all age
combinations and intervals would be very cost-effective, with
the highest life expectancy gains associated with screening at
25 and 35 years. If screening is available three times in a
lifetime, it would be very cost-effective at either 30, 40 and 50
years; 30, 35, and 40 years; or 25, 35, and 45 years (in order of
increasing effectiveness), with an ICER of I$1370 per YLS or
less. Assuming all ages and frequencies considered are avail-
able, screening once in a lifetime at age 30 years, and screening
twice in a lifetime at ages 35 and 45 years or 25 and 35 years are now
dominated. The most effective strategy is screening three times in a
lifetime at 25, 35, and 45 years, which would be very cost-effective
with an ICER of I$1370 per YLS.
Budget impact
For the analysis of budget impact, we converted the direct
medical costs associated with careHPV (cervical sampling),
colposcopy and biopsy, cryotherapy, and LEEP from local
Table A10
Cost-effectiveness of screening by age, frequency, and interval in India (GDP per capita: I$5240)a.
Strategyb Discounted lifetime cost per woman (I$)c Discounted life expectancy (years)c ICER (I$/YLS)d
careHPV (cervical) at 50 years 10.82 27.7950 Dom
VIA at 50 years 10.89 27.7883 Dom
careHPV (vaginal) at 50 years 10.92 27.7936 Dom
careHPV (cervical) at 45 years 11.24 27.7982 190
careHPV (vaginal) at 45 years 11.37 27.7963 Dom
VIA at 45 years 11.40 27.7933 Dom
careHPV (cervical) at 40 years 11.97 27.8000 330
VIA at 40 years 11.97 27.7945 Dom
careHPV (vaginal) at 40 years 12.08 27.7983 Dom
Cytology at 50 years 12.46 27.7900 Dom
VIA at 35 years 12.74 27.7949 Dom
careHPV (cervical) at 35 years 13.06 27.8017 Dom
Cytology at 45 years 13.13 27.7911 Dom
careHPV (vaginal) at 35 years 13.13 27.7997 Dom
VIA at 30 years 13.66 27.7948 Dom
Cytology at 40 years 13.97 27.7918 Dom
careHPV (cervical) at 30 years 13.99 27.8018 Dom
careHPV (vaginal) at 30 years 14.02 27.7996 Dom
VIA at 25 years 14.97 27.7926 Dom
Cytology at 35 years 15.01 27.7920 Dom
VIA at 35 & 45 years 15.45 27.8000 Dom
careHPV (cervical) at 35 & 45 years 15.88 27.8105 390
careHPV (vaginal) at 35 & 45 years 15.96 27.8076 Dom
Cytology at 30 years 16.22 27.7919 Dom
careHPV (vaginal) at 25 years 16.62 27.7919 Dom
careHPV (cervical) at 25 years 16.71 27.7997 Dom
VIA at 30 & 40 years 16.93 27.8024 Dom
careHPV (cervical) at 30 & 40 years 17.53 27.8126 Dom
careHPV (vaginal) at 30 & 40 years 17.55 27.8095 Dom
Cytology at 25 years 17.88 27.7897 Dom
VIA at 35, 40, & 45 years 18.96 27.8068 Dom
VIA at 30, 40, & 50 18.96 27.8068 Dom
Cytology at 35 & 45 years 19.33 27.7970 Dom
careHPV (vaginal) at 35, 40, & 45 years 19.87 27.8138 Dom
careHPV (cervical) at 35, 40, & 45 years 19.91 27.8168 Dom
careHPV (vaginal) at 30, 40, & 50 years 20.06 27.8142 Dom
careHPV (cervical) at 30, 40, & 50 years 20.07 27.8178 580
VIA at 30, 35, & 40 years 21.20 27.8081 Dom
careHPV (vaginal) at 25 & 35 years 21.23 27.8091 Dom
careHPV (cervical) at 25 & 35 years 21.34 27.8116 Dom
Cytology at 30 & 40 years 21.37 27.7977 Dom
VIA at 25 & 35 years 21.52 27.7983 Dom
VIA at 25, 35, & 45 years 21.77 27.8067 Dom
careHPV (vaginal) at 30, 35, & 40 years 22.50 27.8164 Dom
careHPV (cervical) at 30, 35, & 40 years 22.62 27.8194 1600
careHPV (vaginal) at 25, 35, & 45 years 24.22 27.8157 Dom
careHPV (cervical) at 25, 35, & 45 years 24.35 27.8189 Dom
Cytology at 35, 40, & 45 years 24.57 27.8019 Dom
Cytology at 30, 40, & 50 years 25.04 27.8025 Dom
Cytology at 30, 35, & 40 years 27.65 27.8025 Dom
Cytology at 25, 35, & 45 years 28.39 27.8009 Dom
a Dom: dominated strategy (i.e., those that are more costly and less effective, or have higher ICERs than more effective options); GDP: gross domestic product; ICER:
incremental cost-effectiveness ratio; I$: 2011 international dollars; YLS: year of life saved.
b Strategies are listed in order of increasing cost.
c Discounted costs and life expectancies starting from age 9.
d ICERs are presented as the ratio of the mean costs divided by the mean effects of one strategy versus another across the top 50 input parameter sets.
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currency units to 2013 US$ using GDP deﬂators and ofﬁcial
exchange rates. We assumed the cost of the test kit was stable at
a cost of US$5. The expected direct medical costs per woman
screened are presented in Table A14.
Alternative natural history inputs, India
For the majority of good-ﬁtting input parameter sets in the
India model, model-projected cancer incidence fell below the 95%
conﬁdence interval suggested by registry data for age 40 and
above. We explored alternative scoring algorithms that empha-
sized ﬁt to cancer incidence at older ages, but this resulted in HPV
prevalence projections above the target bounds. To assess the
impact of this uncertainty in cancer incidence, we repeated
the analysis with 3 alternative parameter sets that had either
(1) reduced HPV incidence for non-HPV16/18/33 types and red-
uced CIN3 regression for non-HPV16 types; or (2) reduced HPV
incidence for non-HPV16/18/33 types and reduced CIN3 regression
for all high-risk types. Model projections for high-risk HPV
prevalence and cancer incidence, relative to the calibration targets
Table A11
Cost-effectiveness of screening by age, frequency, and interval in Nicaragua (GDP per capita: I$4220) a.
Strategyb Discounted lifetime cost per woman (I$)c Discounted life expectancy (years)c ICER (I$/YLS)d
careHPV (cervical) at 35 years 40.98 28.6404 CS
careHPV (cervical) at 40 years 41.41 28.6290 Dom
careHPV (cervical) at 30 years 41.47 28.6483 Dom
careHPV (cervical) at 45 years 42.03 28.6174 Dom
careHPV (vaginal) at 35 years 42.08 28.6322 Dom
careHPV (vaginal) at 40 years 42.33 28.6223 Dom
careHPV (cervical) at 35 & 45 years 42.59 28.6627 Dom
careHPV (vaginal) at 30 years 42.60 28.6390 Dom
VIA at 35 years 42.63 28.6283 Dom
careHPV (cervical) at 50 years 42.66 28.6070 Dom
VIA at 40 years 42.74 28.6204 Dom
careHPV (vaginal) at 45 years 42.78 28.6122 Dom
careHPV (cervical) at 30 & 40 years 42.98 28.6790 50
VIA at 45 years 43.05 28.6114 Dom
careHPV (vaginal) at 50 years 43.22 28.6033 Dom
VIA at 30 years 43.52 28.6329 Dom
careHPV (vaginal) at 35 & 45 years 43.82 28.6527 Dom
careHPV (cervical) at 25 years 44.17 28.6488 Dom
careHPV (vaginal) at 30 & 40 years 44.27 28.6671 Dom
VIA at 35 & 45 years 44.47 28.6491 Dom
VIA at 50 years 44.75 28.5877 Dom
careHPV (vaginal) at 25 years 44.84 28.6407 Dom
VIA at 30 & 40 years 45.29 28.6611 Dom
careHPV (cervical) at 30, 40, & 50 years 45.48 28.6905 Dom
Cytology at 50 years 45.78 28.5909 Dom
careHPV (cervical) at 25 & 35 years 45.91 28.6871 Dom
VIA at 25 years 46.00 28.6264 Dom
careHPV (cervical) at 35, 40, & 45 years 46.04 28.6827 Dom
Cytology at 45 years 46.23 28.5941 Dom
careHPV (vaginal) at 30, 40, & 50 years 46.75 28.6779 Dom
Cytology at 40 years 46.80 28.5975 Dom
careHPV (vaginal) at 25 & 35 years 46.84 28.6753 Dom
careHPV (vaginal) at 35, 40, & 45 years 47.04 28.6722 Dom
careHPV (cervical) at 30, 35, & 40 years 47.21 28.7030 180
Cytology at 35 years 47.62 28.6001 Dom
VIA at 35, 40, & 45 years 47.80 28.6687 Dom
VIA at 30, 40, & 50 years 47.84 28.6642 Dom
careHPV (vaginal) at 30, 35, & 40 years 48.27 28.6907 Dom
careHPV (cervical) at 25, 35, & 45 years 48.46 28.7040 1200
Cytology at 30 years 48.84 28.6011 Dom
VIA at 30, 35, & 40 years 49.22 28.6844 Dom
careHPV (vaginal) at 25, 35, & 45 years 49.41 28.6912 Dom
VIA at 25, 35, & 45 years 50.21 28.6798 Dom
Cytology at 25 years 51.03 28.5966 Dom
Cytology at 35 & 45 years 51.34 28.6110 Dom
VIA at 25 & 35 years 51.94 28.6379 Dom
Cytology at 30 & 40 years 53.17 28.6155 Dom
Cytology at 35, 40, & 45 years 55.93 28.6235 Dom
Cytology at 25 & 35 years 56.09 28.6136 Dom
Cytology at 30, 40, & 50 years 56.54 28.6229 Dom
Cytology at 30, 35, & 40 years 58.50 28.6299 Dom
Cytology at 25, 35, & 45 years 59.91 28.6240 Dom
a CS: cost-saving; Dom: dominated strategy (i.e., those that are more costly and less effective, or have higher ICERs than more effective options); GDP: gross domestic
product; ICER: incremental cost-effectiveness ratio; I$: 2011 international dollars; YLS: year of life saved.
b Strategies are listed in order of increasing cost.
c Discounted costs and life expectancies starting from age 9.
d ICERs are presented as the ratio of the mean costs divided by the mean effects of one strategy versus another across the top 50 input parameter sets.
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and the 50 good-ﬁtting input parameter sets used for the main
analysis, are displayed in Figs. A13 and A14.
When screening with careHPV (cervical sampling) was com-
pared at various ages assuming a set frequency, ICERs were
generally similar to results from 50 sets (Table A15). For screening
three times in a lifetime, screening at 30, 35, and 40 was no longer
attractive, but screening at 25, 35, and 45 was a ranking strategy,
albeit with a high ICER. For screening once, twice, or three times in
a lifetime, screening once at 40 years was no longer a ranking
strategy, and screening three times at 30, 35, and 40 was not a
ranking strategy, but screening at 25, 35, and 45 years was a
ranking strategy (again, with a high ICER). Findings indicate that
results are robust for the 50 parameter sets in the main analysis.
Sensitivity analyses
We explored the impact of varying the proportion of eligible
women receiving immediate cryosurgery following careHPV
results, setting the base case proportion of 0.8 to 0.7, to be
consistent with VIA (in the main analysis, we assumed women
Table A12
Cost-effectiveness of screening by age, frequency, and interval in Uganda (GDP per capita: I$1370) a.
Strategyb Discounted lifetime cost per woman (I$)c Discounted life expectancy (years)c ICER (I$/YLS)d
VIA at 50 years 14.98 25.2122 Dom
careHPV (cervical) at 50 years 15.60 25.2249 Dom
careHPV (vaginal) at 50 years 15.67 25.2221 Dom
VIA at 45 years 16.23 25.2312 Dom
careHPV (cervical) at 45 years 16.49 25.2345 Dom
careHPV (vaginal) at 45 years 16.58 25.2306 Dom
VIA at 40 years 17.13 25.2402 Dom
careHPV (cervical) at 40 years 17.60 25.2454 120
careHPV (vaginal) at 40 years 17.70 25.2405 Dom
VIA at 35 years 18.36 25.2476 Dom
careHPV (cervical) at 35 years 19.14 25.2548 160
careHPV (vaginal) at 35 years 19.23 25.2492 Dom
VIA at 30 years 20.06 25.2518 Dom
Cytology at 50 years 20.12 25.2155 Dom
careHPV (cervical) at 30 years 20.55 25.2602 Dom
careHPV (vaginal) at 30 years 20.62 25.2540 Dom
Cytology at 45 years 22.15 25.2204 Dom
VIA at 25 years 22.36 25.2469 Dom
VIA at 35 & 45 years 22.65 25.2675 Dom
careHPV (cervical) at 35 & 45 years 23.77 25.2755 Dom
careHPV (vaginal) at 35 & 45 years 23.83 25.2684 Dom
careHPV (vaginal) at 25 years 23.86 25.2548 Dom
careHPV (cervical) at 25 years 23.92 25.2595 Dom
Cytology at 40 years 24.51 25.2256 Dom
VIA at 30 & 40 years 25.35 25.2789 Dom
careHPV (cervical) at 30 & 40 years 26.42 25.2889 210
careHPV (vaginal) at 30 & 40 years 26.45 25.2808 Dom
Cytology at 35 years 27.43 25.2299 Dom
VIA at 30, 40, & 50 28.22 25.2845 Dom
VIA at 35, 40, & 45 years 28.46 25.2848 Dom
careHPV (vaginal) at 35, 40, & 45 years 30.03 25.2856 Dom
careHPV (cervical) at 35, 40, & 45 years 30.10 25.2925 Dom
careHPV (vaginal) at 30, 40, & 50 years 30.26 25.2912 Dom
careHPV (cervical) at 30, 40, & 50 years 30.27 25.2998 350
Cytology at 30 years 30.88 25.2318 Dom
careHPV (vaginal) at 25 & 35 years 31.33 25.2874 Dom
careHPV (cervical) at 25 & 35 years 31.44 25.2948 Dom
VIA at 30, 35, & 40 years 32.59 25.2993 Dom
VIA at 25, 35, & 45 years 33.41 25.2972 Dom
careHPV (vaginal) at 30, 35, & 40 years 34.36 25.3018 Dom
careHPV (cervical) at 30, 35, & 40 years 34.48 25.3099 420
Cytology at 25 years 35.15 25.2281 Dom
careHPV (vaginal) at 25, 35, & 45 years 36.15 25.3029 Dom
careHPV (cervical) at 25, 35, & 45 years 36.31 25.3112 1370
Cytology at 35 & 45 years 37.29 25.2447 Dom
VIA at 25 & 35 years 39.64 25.2662 Dom
Cytology at 30 & 40 years 43.16 25.2519 Dom
Cytology at 35, 40, & 45 years 49.75 25.2606 Dom
Cytology at 25 & 35 years 50.35 25.2519 Dom
Cytology at 30, 40, & 50 years 51.09 25.2614 Dom
Cytology at 30, 35, & 40 years 58.60 25.2699 Dom
Cytology at 25, 35, & 45 years 60.33 25.2654 Dom
a Dom: dominated strategy (i.e., those that are more costly and less effective, or have higher ICERs than more effective options); GDP: gross domestic product; ICER:
incremental cost-effectiveness ratio; I$: 2011 international dollars; YLS: year of life saved.
b Strategies are listed in order of increasing cost.
c Discounted costs and life expectancies starting from age 9.
d ICERs are presented as the ratio of the mean costs divided by the mean effects of one strategy versus another across the top 50 input parameter sets.
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Table A13
Cost-effectiveness of screening with careHPV (cervical sampling) by frequency in India, Nicaragua, and Uganda a.
Strategyb Discounted lifetime cost per woman (I$) Discounted life expectancy (years) ICER (I$/YLS)c
India (GDP per capita: I$5240)
Screening once in a lifetimed
careHPV (cervical) at 50 years 10.82 27.7950 Dom
careHPV (cervical) at 45 years 11.24 27.7982 190
careHPV (cervical) at 40 years 11.97 27.8000 330
careHPV (cervical) at 35 years 13.06 27.8017 780
careHPV (cervical) at 30 years 13.99 27.8018 22,410
careHPV (cervical) at 25 years 16.71 27.7997 Dom
Screening twice in a lifetimee
careHPV (cervical) at 35 & 45 years 15.88 27.8105 280
careHPV (cervical) at 30 & 40 years 17.53 27.8126 760
careHPV (cervical) at 25 & 35 years 21.34 27.8116 Dom
Screening three times in a lifetimef
careHPV (cervical) at 35, 40, & 45 years 19.91 27.8168 Dom
careHPV (cervical) at 30, 40, & 50 years 20.07 27.8178 350
careHPV (cervical) at 30, 35, & 40 years 22.62 27.8194 1600
careHPV (cervical) at 25, 35, & 45 years 24.35 27.8189 Dom
Screening once, twice, or three times in a lifetimeg
careHPV (cervical) at 50 years 10.82 27.7950 Dom
careHPV (cervical) at 45 years 11.24 27.7982 190
careHPV (cervical) at 40 years 11.97 27.8000 330
careHPV (cervical) at 35 years 13.06 27.8017 Dom
careHPV (cervical) at 30 years 13.99 27.8018 Dom
careHPV (cervical) at 35 & 45 years 15.88 27.8105 390
careHPV (cervical) at 25 years 16.71 27.7997 Dom
careHPV (cervical) at 30 & 40 years 17.53 27.8126 Dom
careHPV (cervical) at 35, 40, & 45 years 19.91 27.8168 Dom
careHPV (cervical) at 30, 40, & 50 years 20.07 27.8178 580
careHPV (cervical) at 25 & 35 years 21.34 27.8116 Dom
careHPV (cervical) at 30, 35, & 40 years 22.62 27.8194 1600
careHPV (cervical) at 25, 35, & 45 years 24.35 27.8189 Dom
Nicaragua (GDP per capita: I$4220)
Screening once in a lifetimed
careHPV (cervical) at 35 years 40.98 28.6404 CS
careHPV (cervical) at 40 years 41.41 28.6290 Dom
careHPV (cervical) at 30 years 41.47 28.6483 60
careHPV (cervical) at 45 years 42.03 28.6174 Dom
careHPV (cervical) at 50 years 42.66 28.6070 Dom
careHPV (cervical) at 25 years 44.17 28.6488 5750
Screening twice in a lifetimee
careHPV (cervical) at 35 & 45 years 42.59 28.6627 CS
careHPV (cervical) at 30 & 40 years 42.98 28.6790 20
careHPV (cervical) at 25 & 35 years 45.91 28.6871 360
Screening three times in a lifetimef
careHPV (cervical) at 30, 40, & 50 years 45.48 28.6905 30
careHPV (cervical) at 35, 40, & 45 years 46.04 28.6827 Dom
careHPV (cervical) at 30, 35, & 40 years 47.21 28.7030 140
careHPV (cervical) at 25, 35, & 45 years 48.46 28.7040 1200
Screening once, twice, or three times in a lifetimeg
careHPV (cervical) at 35 years 40.98 28.6404 CS
careHPV (cervical) at 40 years 41.41 28.6290 Dom
careHPV (cervical) at 30 years 41.47 28.6483 Dom
careHPV (cervical) at 45 years 42.03 28.6174 Dom
careHPV (cervical) at 35 & 45 years 42.59 28.6627 Dom
careHPV (cervical) at 50 years 42.66 28.6070 Dom
careHPV (cervical) at 30 & 40 years 42.98 28.6790 50
careHPV (cervical) at 25 years 44.17 28.6488 Dom
careHPV (cervical) at 30, 40, & 50 years 45.48 28.6905 Dom
careHPV (cervical) at 25 & 35 years 45.91 28.6871 Dom
careHPV (cervical) at 35, 40, & 45 years 46.04 28.6827 Dom
careHPV (cervical) at 30, 35, & 40 years 47.21 28.7030 180
careHPV (cervical) at 25, 35, & 45 years 48.46 28.7040 1200
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might be more likely to delay cryotherapy after VIA than with 2-
visit HPV testing, when they would have already received counsel-
ing in the screening visit). Varying the proportion receiving
immediate cryosurgery during the results visit had no impact on
the rank order of strategies, and careHPV (cervical sampling)
remained the dominant strategy. The ICERs associated with
careHPV (cervical sampling) changed little. In Uganda, the ICER
Table A13 (continued )
Strategyb Discounted lifetime cost per woman (I$) Discounted life expectancy (years) ICER (I$/YLS)c
Uganda (GDP per capita: I$1370)
Screening once in a lifetimed
careHPV (cervical) at 50 years 15.60 25.2249 Dom
careHPV (cervical) at 45 years 16.49 25.2346 Dom
careHPV (cervical) at 40 years 17.60 25.2454 120
careHPV (cervical) at 35 years 19.14 25.2548 160
careHPV (cervical) at 30 years 20.55 25.2602 260
careHPV (cervical) at 25 years 23.92 25.2595 Dom
Screening twice in a lifetimee
careHPV (cervical) at 35 & 45 years 23.77 25.2755 160
careHPV (cervical) at 30 & 40 years 26.42 25.2889 200
careHPV (cervical) at 25 & 35 years 31.44 25.2948 840
Screening three times in a lifetimef
careHPV (cervical) at 35, 40, & 45 years 30.10 25.2925 Dom
careHPV (cervical) at 30, 40, & 50 years 30.27 25.2999 180
careHPV (cervical) at 30, 35, & 40 years 34.48 25.3099 420
careHPV (cervical) at 25, 35, & 45 years 36.31 25.3112 1370
Screening once, twice, or three times in a lifetimeg
careHPV (cervical) at 50 years 15.60 25.2249 Dom
careHPV (cervical) at 45 years 16.49 25.2346 Dom
careHPV (cervical) at 40 years 17.60 25.2454 120
careHPV (cervical) at 35 years 19.14 25.2548 160
careHPV (cervical) at 30 years 20.55 25.2602 Dom
careHPV (cervical) at 35 & 45 years 23.77 25.2755 Dom
careHPV (cervical) at 25 years 23.92 25.2595 Dom
careHPV (cervical) at 30 & 40 years 26.42 25.2889 210
careHPV (cervical) at 35, 40, & 45 years 30.10 25.2925 Dom
careHPV (cervical) at 30, 40, & 50 years 30.27 25.2999 350
careHPV (cervical) at 25 & 35 years 31.44 25.2948 Dom
careHPV (cervical) at 30, 35, & 40 years 34.48 25.3099 420
careHPV (cervical) at 25, 35, & 45 years 36.31 25.3112 1370
a CS: cost saving; Dom: dominated strategy (i.e., those that are more costly and less effective, or have higher ICERs than more effective options); GDP: gross domestic
product; ICER: incremental cost-effectiveness ratio; I$: 2011 international dollars; YLS: year of life saved.
b Strategies are listed in order of increasing cost. For this table, we have assumed only careHPV (cervical sampling), the dominant screening strategy, was available.
c ICERs are presented as the ratio of the mean costs divided by the mean effects of one strategy versus another across the top 50 input parameter sets.
d Assuming screening will take place once in a lifetime, at one of the ages evaluated.
e Assuming screening will take place twice in a lifetime, at one of the age combinations considered.
f Assuming screening will take place three times in a lifetime, at one of the age combinations considered.
g Assuming screening will take place once, twice, or three times in a lifetime, at one of the age combinations considered.
Table A14
Budget impact: Expected direct medical cost per woman screened, by country and
age, 2013 US$.
Age Expected direct medical cost per woman screened
India Nicaragua Uganda
25 7.14 12.41 7.87
30 6.73 11.57 7.34
35 6.73 11.30 7.12
40 6.56 10.91 6.63
45 6.37 10.53 6.12
50 6.17 10.15 5.57
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Fig. A13. Model ﬁt of 3 alternative input parameter sets, India: high-risk HPV
prevalence. The black lines represent the 95% conﬁdence interval around the
empirical data [7], and the gray dots represent model-predicted prevalence of high-
risk HPV from the 50 good-ﬁtting input parameter sets used in the main analysis.
Blue diamonds represent the ﬁt of the alternative 3 sets used for sensitivity
analysis. (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article.)
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for screening with careHPV (cervical sampling) at ages 25, 35, and
45 years increased from I$1370 per YLS to I$1520, which given
Uganda’s per capita GDP of I$1370 would be considered cost-
effective, but no longer very cost-effective.
When we varied loss to follow-up associated with each clinical
encounter relative to the previous visit (including the results visit
for HPV testing, or diagnostic conﬁrmation and treatment visits for
women who are ineligible for cryosurgery in a screen-and-treat
approach) from 15% in the base case to 30%, careHPV (cervical
sampling) remained the dominant strategy in India and Nicaragua,
with ICERs increasing slightly as screening costs were more frequently
incurred without corresponding health beneﬁts. In Uganda, where VIA
test sensitivity in the START–UP project was higher than other sites
(74%), VIA became the dominant screening strategy.
Supplementary discussion
There are several limitations to this analysis, which are pri-
marily documented in the paper. We elaborate further here. With
regards to potential interaction between HIV and cervical cancer,
we did not explicitly model an altered natural history in HIV-
infected women due to data limitations. Instead, we calibrated our
model to the general population of women in Uganda, assuming
the model output reﬂects the course of HPV natural history at the
population level, including high-risk subgroups.
Regarding costing estimates, we did not include the cost of
treatment-associated complications, as these were very rare in the
START–UP studies. As primary data on cancer costs in Nicaragua and
Ugandawere unavailable, these were extrapolated from primary data
in El Salvador and Kenya, respectively, as described above. While our
extrapolation technique explicitly considered differences in health
care costs and GDP per capita between Nicaragua and El Salvador, the
cancer costs in Nicaragua were relatively high compared to screening
costs, and thus screening with careHPV was either cost-saving or had
a very low ICER. If cancer costs in Nicaragua are in fact lower, scree-
ning would appear somewhat less attractive.
Data on loss to follow-up between screening and treatment are
limited, so we assumed that 15% of women were lost between
each subsequent visit to receive screening results or diagnostic
conﬁrmation and treatment of histologically conﬁrmed lesions
(when applicable). This may be an underestimate, if attrition rates
are closer to 40% suggested by a study from South Africa [63];
however, the same study found that community health worker
contact improved follow-up rates substantially.
Cancer incidence data for Nicaragua were drawn from GLOBO-
CAN, rather than a cancer registry. Cancer incidence data for India
(Hyderabad) were based on the Nagpur registry, which may not
reﬂect cancer incidence in Hyderabad, although cancer incidence
in Nagpur appears to be similar to incidence rates documented by
several other urban registries in northern and central India (i.e.,
Bhopal and Delhi).
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